6533b839fe1ef96bd12a69fe

RESEARCH PRODUCT

Progress Report The ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudy of InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useof tumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease

A OrlandoA ArmuzziC PapiVito AnneseS ArdizzoneL BianconeA BortoliF CastiglioneR D’inca'P GionchettiA KohnG PoggioliF RizzelloM VecchiMario Cottone

subject

Guidelines.Biologics.Inflammatory bowel disease.

description

Biological therapiesareanimportantstepinthemanagementofInflammatoryBowelDiseases.Incon- sideration ofhighcostandsafetyissuesthereistheneedtohaveclearrecommendationsfortheiruse. Despite theAmericanGastroenterologicalAssociationandtheEuropeanCrohn’sandColitisOrganisation have publishedexhaustiveInflammatoryBowelDiseaseguidelines,nationalguidelinesmaybeneces- sary asculturalvalues,economicalandlegalissuesmaydifferbetweencountries.Forthesereasonsthe Italian SocietyofGastroenterologyandtheItalianGroupforthestudyofInflammatoryBowelDisease have decidedtoelaboratetheItalianguidelinesontheuseofbiologicsinInflammatoryBowelDisease. The followingitemshavebeenchosen:definitionsofactive,inactive,steroiddependentandresistant disease; measuresofactivity;anti-tumornecrosisfactoralphatherapyuseinactivesteroiddependent and refractoryluminalCrohn’sDisease,infistulisingCrohn’sDisease,insteroiddependentandresistant active UlcerativeColitis;riskofcancer;riskofinfectionsduringanti-tumornecrosisfactoralphatherapy; special situations.Theseguidelinesarebasedonevidencefromrelevantmedicalliteratureandclinical experience ofanationalworkinggroup.

http://hdl.handle.net/10447/53766